Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau

Algernon Pharmaceuticals CEO, Christopher J. Moreau joins Cyndi Edwards, host of PRmediaNow to discuss the company’s DMT Stroke Program and provides an update and recap on the recent news regarding the filing of a Pre-IND Meeting Request with the U.S. FDA.